Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Dual MEK inhibitor IMM-1-104 may be an improvement over approved MEK inhibitors

Oct. 18, 2021

PRT-2527 shows efficacy in models of hematological and solid tumors with MYC dysregulation

Oct. 18, 2021

AstraZeneca synthesizes new cannabinoid CB1 receptor antagonists

Oct. 18, 2021

Gritscience Biopharmaceuticals identifies casein kinase 1 isoform delta inhibitors

Oct. 18, 2021

Janssen Pharmaceutica patents MGLL inhibitors

Oct. 18, 2021

PDAC priming boosts chemotherapeutic efficacy

Oct. 18, 2021

DeoBioSciences reports preclinical data on DBX-31 in advanced cancers

Oct. 15, 2021

Exelixis and Storm Therapeutics collaborate to advance novel drug leads for cancer

Oct. 15, 2021

IL-36gamma-based therapy modulates immune response in pancreatic cancer models

Oct. 15, 2021

IntoCell and Ab Studio establish research collaboration to combine antibody and linker capabilities

Oct. 15, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.